The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(E)-N-(4-(3-([1,4'-bipiperidin]-1'-yl)prop-1-en-1-yl)benzyl)-N-neopentyl-6-(trifluoromethyl)-pyrimidin-4-amine ID: ALA4077221
PubChem CID: 137651896
Max Phase: Preclinical
Molecular Formula: C30H42F3N5
Molecular Weight: 529.70
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: CC(C)(C)CN(Cc1ccc(/C=C/CN2CCC(N3CCCCC3)CC2)cc1)c1cc(C(F)(F)F)ncn1
Standard InChI: InChI=1S/C30H42F3N5/c1-29(2,3)22-38(28-20-27(30(31,32)33)34-23-35-28)21-25-11-9-24(10-12-25)8-7-15-36-18-13-26(14-19-36)37-16-5-4-6-17-37/h7-12,20,23,26H,4-6,13-19,21-22H2,1-3H3/b8-7+
Standard InChI Key: PTDQNFUQDMYFGK-BQYQJAHWSA-N
Molfile:
RDKit 2D
38 41 0 0 0 0 0 0 0 0999 V2000
2.5023 -27.8902 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5011 -28.7201 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2188 -29.1323 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.9381 -28.7196 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9353 -27.8865 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.2170 -27.4740 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2145 -26.6464 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.9306 -26.2324 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4960 -26.2368 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4935 -25.4091 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7750 -24.9953 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2096 -24.9910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4871 -24.5796 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6450 -26.6420 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6453 -27.4670 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3630 -27.8807 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0800 -27.4626 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0749 -26.6308 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3566 -26.2250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7970 -27.8718 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.5080 -27.4565 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.2233 -27.8647 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.9343 -27.4493 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
9.6489 -27.8606 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.3579 -27.4487 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.3580 -26.6249 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.6429 -26.2145 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.9278 -26.6280 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.0665 -26.2144 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
11.7800 -26.6274 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.4905 -26.2183 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.4938 -25.3945 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.7803 -24.9815 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.0635 -25.3922 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7868 -29.1329 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7872 -29.9579 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
0.9899 -28.9194 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1.0723 -29.5454 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
6 7 1 0
7 8 1 0
7 9 1 0
9 10 1 0
10 11 1 0
10 12 1 0
10 13 1 0
8 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 14 1 0
17 20 1 0
20 21 2 0
21 22 1 0
22 23 1 0
23 24 1 0
23 28 1 0
24 25 1 0
25 26 1 0
26 27 1 0
27 28 1 0
29 30 1 0
29 34 1 0
30 31 1 0
31 32 1 0
32 33 1 0
33 34 1 0
26 29 1 0
2 35 1 0
35 36 1 0
35 37 1 0
35 38 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 529.70Molecular Weight (Monoisotopic): 529.3392AlogP: 6.51#Rotatable Bonds: 8Polar Surface Area: 35.50Molecular Species: BASEHBA: 5HBD: ┄#RO5 Violations: 2HBA (Lipinski): 5HBD (Lipinski): ┄#RO5 Violations (Lipinski): 2CX Acidic pKa: ┄CX Basic pKa: 10.05CX LogP: 6.79CX LogD: 4.16Aromatic Rings: 2Heavy Atoms: 38QED Weighted: 0.39Np Likeness Score: -1.03
References 1. Miltz W, Velcicky J, Dawson J, Littlewood-Evans A, Ludwig MG, Seuwen K, Feifel R, Oberhauser B, Meyer A, Gabriel D, Nash M, Loetscher P.. (2017) Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis., 25 (16): [PMID:28689977 ] [10.1016/j.bmc.2017.06.050 ]